Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4006-4011

  Pai, Manjunath P ^a   Nafziger, Anne N ^b   Bertino Jr , Joseph S ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b BERTINO CONSULTING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; GENTAMICIN; TOBRAMYCIN;

ADULT; AGE; ARTICLE; BODY MASS; BODY SIZE; BODY WEIGHT; CLINICAL ASSESSMENT TOOL; DISEASE CLASSIFICATION; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HEALTH; HUMAN; KIDNEY FUNCTION; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; UNDERWEIGHT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; BODY MASS INDEX; FEMALE; GENTAMICINS; GLOMERULAR FILTRATION RATE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; THINNESS; TOBRAMYCIN; YOUNG ADULT;

EID: 80051820779     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00174-11     Document Type: Article

References (38)

1. Armstrong, E S, and G H Miller. Combating evolution with intelligent design: The neoglycoside ACHN-490. Curr. Opin. Microbiol. 13:565-573.
2. Bauer, L A, W A Edwards, E P Dellinger, and D A Simonowitz. 1983. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur. J. Clin. Pharmacol. 24:643-647. (Pubitemid 13092243)
3. B. Braun Medical Inc. 2007. Gentamicin sulfate in 0.9% sodium chloride for injection. B. Braun Medical Inc., Bethlehem, PA.
4. Cockcroft, D W, and M H Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
5. Craig, W A Optimizing aminoglycoside use. Crit. Care Clin. 27:107-121.
6. Demirovic, J A, A B Pai, and M P Pai. 2009. Estimation of creatinine clearance in morbidly obese patients. Am. J. Health Syst. Pharm. 66:642-648.
7. Devine, B J 1974. Gentamicin therapy. Drug Intell. Clin. Pharm. 8:650-655.
8. Flegal, K M, M D Carroll, C L Ogden, and L R Curtin. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-241.
9. Food and Drug Administration. 2010. Pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. Clinical pharmacology. Draft guidance. Food and Drug Administration, U.S. Department of Health and Human Services, Washington, DC.
10. Green, B, and S B Duffull. 2004. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br. J. Clin. Pharmacol. 58:119-133. (Pubitemid 39043992)
11. Hirsch, E B, and V H Tam. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother. 65:1119-1125.
12. Houghton, J L, K D Green, W. Chen, and S. Garneau-Tsodikova. The future of aminoglycosides: The end or renaissance? Chembiochem 11:880-902.
13. Janmahasatian, S., et al. 2005. Quantification of lean bodyweight. Clin. Pharmacokinet. 44:1051-1065. (Pubitemid 41356391)
14. Lau, A H, S I Berk, T. Prosser, and T. Stonich. 1988. Estimation of creatinine clearance in malnourished patients. Clin. Pharm. 7:62-65.
15. Levey, A S, et al. 2007. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin. Chem. 53:766-772. (Pubitemid 46580250)
16. Levey, A S, et al. 2009. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150:604-612.
17. Mosteller, R D 1987. Simplified calculation of body-surface area. N. Engl. J. Med. 317:1098.
18. Mueller, E W, and B A Boucher. 2009. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. Surg. Infect. (Larchmt.) 10:563-570.
19. Murphy, J E 2008. Aminoglycosides. In Clinical pharmacokinetics, 4th ed. American Society of Health Systems Pharmacists, Bethesda, MD.
20. National Kidney Disease Education Program. January 2010, posting date. Chronic kidney disease and drug dosing: information for providers. National Kidney Disease Education Program, Bethesda, MD. http://www.nkdep.nih.gov/ professionals/drug-dosing-information.htm.
21. Ogden, C L, C D Fryar, M D Carroll, and K M Flegal. 2004. Mean body weight, height, and body mass index, United States 1960-2002. Adv. Data, p. 1-17.
22. Pai, M P Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv. Chronic Kidney Dis. 17:e53-e62.
23. Pai, M P, and D T Bearden. 2007. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 27:1081-1091.
24. Pai, M P, and F P Paloucek. 2000. The origin of the "ideal" body weight equations. Ann. Pharmacother. 34:1066-1069. (Pubitemid 30660784)
25. Prescott, W A, Jr., and J L Nagel. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Pharmacotherapy 30:95-108.
26. Sawchuk, R J, and D E Zaske. 1976. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients. J. Pharmacokinet. Biopharm. 4:183-195. (Pubitemid 8133359)
27. Sicor Pharmaceuticals Inc. 2005. Tobramycin injection, USP. Sicor Pharmaceuticals Inc., Irvine, CA.
28. Spruill, W J, W E Wade, and H H Cobb III. 2009. Continuing the use of the Cockcroft-Gault equation for drug dosing in patients with impaired renal function. Clin. Pharmacol. Ther. 86:468-470.
29. Stevens, L A, et al. 2011. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int. 79:555-562.
30. Stevens, L A, and A S Levey. 2009. Use of the MDRD study equation to estimate kidney function for drug dosing. Clin. Pharmacol. Ther. 86:465-467.
31. Streetman, D S, A N Nafziger, C J Destache, and A S Bertino, Jr. 2001. Individualized pharmacokinetic monitoring results in less aminoglycosideassociated nephrotoxicity and fewer associated costs. Pharmacotherapy 21:443-451. (Pubitemid 32275273)
32. Traynor, A M, A N Nafziger, and J S Bertino, Jr. 1995. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob. Agents Chemother. 39:545-548.
33. Turnidge, J. 2003. Pharmacodynamics and dosing of aminoglycosides. Infect. Dis. Clin. North Am. 17:503-528. (Pubitemid 38029150)
34. United Therapeutics Corp. 2008. Remodulin® (treprostinil sodium) injection. United Therapeutics Corp., Research Triangle Park, NC.
35. Van Acker, B A, G C Koomen, M G Koopman, D R De Waart, and L. Arisz. 1992. Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 340:1326-1329.
36. World Health Organization. 2011, posting date. BMI classification. World Health Organization, Geneva, Switzerland. http://apps.who.int/bmi/index.jsp? introPage=intro-3.html.
37. X-Gen Pharmaceuticals Inc. 2010. Colisthemate for injection, USP. X-Gen Pharmaceuticals Inc., Big Flats, NY.
38. Zarowitz, B J, S. Robert, and E L Peterson. 1992. Prediction of glomerular filtration rate using aminoglycoside clearance in critically ill medical patients. Ann. Pharmacother. 26:1205-1210.